Author:
Chen Hong-Dou,Zhou Jing,Wen Feng,Zhang Peng-Fei,Zhou Ke-Xun,Zheng Han-Rui,Yang Yu,Li Qiu
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference29 articles.
1. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP (1994) Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86:1086–1091
2. Apatinib got CFDA approval (2015) http://www.xinyaohui.com/news/201502/05/5059.html . Accessed 27 July 2016
3. Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697
4. ClinicalTrials.gov (2015) Apatinib in combination with S-1 as first-line treatment in patients with advanced gastric cancer. https://clinicaltrials.gov/ct2/show/NCT02525237?term=apatinib&rank=25 . Accessed 27 July 2016
5. ClinicalTrials.gov (2016) Apatinib plus docetaxel versus docetaxel as second-line treatment in advanced gastric cancer (AHEAD-301). https://clinicaltrials.gov/ct2/show/NCT02596256?term=apatinib&rank=36 . Accessed 27 July 2016